ClinicalTrials.Veeva

Menu

Reduction of Operating Time by a Smoke Electroprecipitation Device for Acute Cholecystitis (Ultravision)

P

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Unknown

Conditions

Cholecystitis

Treatments

Device: medical device with CE marking (Ultravision ©)

Study type

Interventional

Funder types

Other

Identifiers

NCT03636841
2017-58

Details and patient eligibility

About

The smoke produced by the electric section of the tissues during laparoscopy alters the vision of the operative field and presents potential risks. A new medical device with CE marking (Ultravision ©) has been developed to limit electroprecipitation on the wall and tissues of the abdomen.

The aim of the work is to evaluate the effectiveness of this medical device in laparoscopic cholecystectomy for cholecystitis. It is an intervention for a common pathology where smoke is particularly important due to the tissue inflammation and due to the extensive dissection necessary to perform the surgical procedure.

A randomized double-blinded study will be conducted in two academic hospitals (Marseille North Hospital and Timone, APHM) evaluating the use of a smoke electroprecipitation device (Ultravision ©) during laparoscopic cholecystectomy for cholecystitis operated at the acute phase. A group of 30 patients using the device will be compared to a control group of 30 patients. The evaluation will last thirty days per patient and the duration of inclusion is 2 years.

The main objective is to demonstrate a significant reduction in operating duration by using the device. The secondary objectives are to reduce the CO2 consumption, the surgical incidents and the discomfort of the surgeon related to the smoke.

Full description

Context and purpose of the work:

The smoke produced by the electric section of the tissues during laparoscopy alters the vision of the operative field and presents potential risks. A new medical device with CE marking (Ultravision ©) has been developed to limit electroprecipitation on the wall and tissues of the abdomen.

The aim of the work is to evaluate the effectiveness of this medical device in laparoscopic cholecystectomy for cholecystitis. It is an intervention for a common pathology where smoke is particularly important due to the tissue inflammation and due to the extensive dissection necessary to perform the surgical procedure.

Material and method A randomized double-blinded study will be conducted in two academic hospitals (Marseille North Hospital and Timone, APHM) evaluating the use of a smoke electroprecipitation device (Ultravision ©) during laparoscopic cholecystectomy for cholecystitis operated at the acute phase. A group of 30 patients using the device will be compared to a control group of 30 patients. The evaluation will last thirty days per patient and the duration of inclusion is 2 years.

Expected results The main objective is to demonstrate a significant reduction in operating duration by using the device. The secondary objectives are to reduce the CO2 consumption, the surgical incidents and the discomfort of the surgeon related to the smoke.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult> 18 years old
  • Ability to accept consent
  • Acute documented cholecystitis (pain> 6h, thickening of vesicular wall on ultrasound, biological inflammatory syndrome)
  • Patient operated within 5 days of onset of signs
  • Surgery decided by laparoscopy

Exclusion criteria

Pregnant woman

  • Atcd umbilical abdominal surgery
  • Achievement of the open subcostal intervention
  • Patient under anticoagulant
  • Patient ASA3
  • Age <75 years
  • BMI> 45
  • icteric cholestasis on preoperative laboratory examination

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

EXPERIMENTAL GROUP
Experimental group
Description:
A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
Treatment:
Device: medical device with CE marking (Ultravision ©)
CONTROL GROUP
Active Comparator group
Description:
A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
Treatment:
Device: medical device with CE marking (Ultravision ©)

Trial contacts and locations

1

Loading...

Central trial contact

thierry bege, md

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems